Journal
NATURE REVIEWS CLINICAL ONCOLOGY
Volume 20, Issue 5, Pages 279-280Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41571-023-00731-8
Keywords
-
Categories
Ask authors/readers for more resources
The rapid progress of immunotherapy revolution in oncology lacks the development of companion diagnostic biomarkers to identify ideal target populations. In addition to the established regulatory pathways relying on predefined biomarkers, a novel approach based on post hoc biomarker analysis could significantly enhance the cost-effectiveness of cancer immunotherapy.
The revolution of immunotherapies in oncology has not been matched by the development of companion diagnostic biomarkers able to identify the ideal target populations. Aside from the established pathways for regulatory approval relying on predefined biomarkers, a novel approach based on post hoc biomarker analysis could potentially be instrumental in enhancing the cost-effectiveness of cancer immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available